1 of 1
Story summary
- A study in JAMA Internal Medicine found that 88% of 168 participants accurately identified their eligibility for over-the-counter (OTC) medication abortion after reviewing a prototype label.
- Most participants expressed interest in OTC access.
- Several states have enacted strict abortion laws, creating political challenges.
- The FDA is conducting a safety review of mifepristone.
- Experts argue that the evidence supports OTC availability, despite the political climate complicating the path forward.
